Sona Nanotech preclinical study shows tumor regression in colorectal cancer model

Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the publication of a preclinical study examining the efficacy of its Targeted Hyperthermia Therapy (THT) in combination with immunotherapy for cancer treatment. The study, published in the Journal of Nanobiotechnology, evaluated the therapy in an immunologically “cold” colorectal cancer (CT26) model.